Comparative Pharmacokinetics of a Dual Inhibitor of HIV-1, NBD-14189, in Rats and Dogs with a Proof-of-Concept Evaluation of Antiviral Potency in SCID-hu Mouse Model.

HIV-1 gp120 antagonist SCID-hu mouse model bioavailability dual inhibitors human immunodeficiency virus type 1 (HIV-1) pharmacokinetics (PK)

Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
16 10 2022
Historique:
received: 19 09 2022
revised: 12 10 2022
accepted: 13 10 2022
entrez: 27 10 2022
pubmed: 28 10 2022
medline: 29 10 2022
Statut: epublish

Résumé

We earlier reported substantial progress in designing gp120 antagonists. Notably, we discovered that NBD-14189 is not only the most active gp120 antagonist but also shows antiviral activity against HIV-1 Reverse Transcriptase (RT). We also confirmed its binding to HIV-1 RT by X-ray crystallography. The dual inhibition is highly significant because, intriguingly, this compound bridges the dNTP and NNRTI-binding sites and inhibits the polymerase activity of isolated RT in the enzymatic assay. This novel finding is expected to lead to new avenues in designing a novel class of HIV-1 dual inhibitors. Therefore, we needed to advance this inhibitor to preclinical assessment. To this end, we report the pharmacokinetics (PK) study of NBD-14189 in rats and dogs. Subsequently, we assessed the toxicity and therapeutic efficacy in vivo in the SCID-hu Thy/Liv mouse model. The PK data indicated a favorable half-life (t

Identifiants

pubmed: 36298823
pii: v14102268
doi: 10.3390/v14102268
pmc: PMC9611370
pii:
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIH HHS
ID : R01 AI104416
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201400002C
Pays : United States

Références

Curr Top Med Chem. 2016;16(10):1074-90
pubmed: 26324044
J Antimicrob Chemother. 2018 Jan 01;73(1):109-117
pubmed: 29029095
Clin Exp Immunol. 2015 Dec;182(3):289-301
pubmed: 26332605
J Med Chem. 2020 Feb 27;63(4):1724-1749
pubmed: 32031803
Antimicrob Agents Chemother. 2011 Feb;55(2):722-8
pubmed: 21078951
ChemMedChem. 2018 Nov 6;13(21):2332-2348
pubmed: 30257071
Nat Chem Biol. 2017 Oct;13(10):1115-1122
pubmed: 28825711
Antimicrob Agents Chemother. 2012 Apr;56(4):2162-5
pubmed: 22252805
Antimicrob Agents Chemother. 1998 Aug;42(8):2113-5
pubmed: 9687417
J Antimicrob Chemother. 2014 Mar;69(3):573-81
pubmed: 24128669
Antimicrob Agents Chemother. 1996 Mar;40(3):755-62
pubmed: 8851606
Curr Top Med Chem. 2009;9(11):965-80
pubmed: 19747120
Nat Chem. 2013 Mar;5(3):174-81
pubmed: 23422558
Antimicrob Agents Chemother. 2000 Mar;44(3):783-6
pubmed: 10681360
PLoS One. 2007 Aug 01;2(7):e655
pubmed: 17668043
Bioorg Med Chem. 2013 Dec 15;21(24):7884-9
pubmed: 24189188
Expert Opin Drug Discov. 2019 Dec;14(12):1313-1327
pubmed: 31538500
PLoS One. 2007 Nov 28;2(11):e1251
pubmed: 18043758
ACS Chem Biol. 2006 Dec 20;1(11):702-12
pubmed: 17184135
Antimicrob Agents Chemother. 2013 Dec;57(12):6254-64
pubmed: 24100493
Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5663-8
pubmed: 22451932
Bioorg Med Chem. 2022 Feb 15;56:116588
pubmed: 35030421
J Virol. 1986 Aug;59(2):284-91
pubmed: 3016298
Med Chem. 2013 Mar;9(2):163-76
pubmed: 23016542
J Med Chem. 2018 Jul 26;61(14):6308-6327
pubmed: 29920093
Nat Rev Drug Discov. 2003 Mar;2(3):192-204
pubmed: 12612645
Curr Opin HIV AIDS. 2022 Jan 1;17(1):32-35
pubmed: 34871189
Acta Pharm Sin B. 2022 Jul;12(7):3049-3062
pubmed: 35865092
Antimicrob Agents Chemother. 2012 Jul;56(7):3498-507
pubmed: 22547625
J Biol Chem. 2008 Dec 5;283(49):34045-52
pubmed: 18809675
J Med Chem. 2017 Apr 13;60(7):3124-3153
pubmed: 28266845
PLoS One. 2014 Jan 28;9(1):e85940
pubmed: 24489681
Eur J Med Chem. 2018 Jun 25;154:367-391
pubmed: 29860061
Lancet HIV. 2020 Nov;7(11):e740-e751
pubmed: 33128903
Nat Rev Drug Discov. 2015 Jul;14(7):475-86
pubmed: 26091267
ACS Chem Biol. 2016 Aug 19;11(8):2158-64
pubmed: 27192549
Nat Commun. 2019 Jan 3;10(1):47
pubmed: 30604750
J Med Chem. 2021 Nov 25;64(22):16530-16540
pubmed: 34735153
Virology. 2005 Sep 1;339(2):213-25
pubmed: 15996703

Auteurs

Cheryl A Stoddart (CA)

Division of Experimental Medicine, Department of Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, CA 94110, USA.

Francesca Curreli (F)

Laboratory of Molecular Modeling & Drug Design, New York Blood Center, Lindsley F. Kimball Research Institute, 310 E 67th Street, New York, NY 10065, USA.

Stephen Horrigan (S)

Noble Life Sciences Inc., Woodbine, MD 21784, USA.

Andrea Altieri (A)

EDASA Scientific srls, Via Stingi 37, 66050 San Salvo, Italy.

Alexander V Kurkin (AV)

EDASA Scientific srls, Via Stingi 37, 66050 San Salvo, Italy.

Asim K Debnath (AK)

Laboratory of Molecular Modeling & Drug Design, New York Blood Center, Lindsley F. Kimball Research Institute, 310 E 67th Street, New York, NY 10065, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH